Xin Huang

32PUBLICATIONS
168CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursMedical infection agents (incl. prions)Regenerative medicine (incl. stem cells)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (32)

|Sep 09, 2026
The stress-sensing MARCH5 axis governs blood cancer apoptotic resilience via tractable protein-protein interactions.

|Sep 02, 2026
MAP3K14 (NIK) synonymous variants drive altered splicing to activate NF-κB in mature B-cell malignancies.

|Apr 09, 2025
Re-appraising assays on permeabilized blood cancer cells testing venetoclax or other BH3 mimetic agents selectively targeting pro-survival BCL2 proteins.

Jia-Nan Gong, Tirta M Djajawi, Donia M Moujalled

|Mar 05, 2025
Differential regulation of BAX and BAK apoptotic activity revealed by small molecules.

Kaiming Li, Yu Q Yap, Donia M Moujalled

|Oct 29, 2024
Venetoclax dose escalation rapidly activates a BAFF/BCL-2 survival axis in chronic lymphocytic leukemia.

Meng-Xiao Luo, Tania Tan, Marie Trussart

|Oct 25, 2023
Loss-of-Function but Not Gain-of-Function Properties of Mutant TP53 Are Critical for the Proliferation, Survival, and Metastasis of a Broad Range of Cancer Cells.

Zilu Wang, Matteo Burigotto, Sabrina Ghetti

Pageof 6

Frequent Collaborators

15 joint publications

Andrew W Roberts

7 joint publications

Thomas E Lew

7 joint publications

Mark F van Delft

6 joint publications

Andrew H Wei